Li Y - Search Results

1

Biotransformation Pathways and Metabolite Profiles of Oral [¹⁴C]Alisertib (MLN8237), an Investigational Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors.

Pusalkar S, Zhou X, Li Y, Cohen L, Yang JJ, Balani SK, Xia C, Shyu WC, Lu C, Venkatakrishnan K, Chowdhury SK. Pusalkar S, et al. Among authors: li y. Drug Metab Dispos. 2020 Mar;48(3):217-229. doi: 10.1124/dmd.119.087338. Epub 2020 Jan 7. Drug Metab Dispos. 2020. PMID: 31911485 Free PMC article.

2

Synthesis of a new inhibitor of breast cancer resistance protein with significantly improved pharmacokinetic profiles.

Li Y, Woo J, Chmielecki J, Xia CQ, Liao M, Chuang BC, Yang JJ, Guan MY, Plesescu M, Prakash SR. Li Y, et al. Bioorg Med Chem Lett. 2016 Jan 15;26(2):551-555. doi: 10.1016/j.bmcl.2015.11.077. Epub 2015 Nov 22. Bioorg Med Chem Lett. 2016. PMID: 26642765

3

Absorption, Distribution, and Excretion of the Investigational Agent Orteronel (TAK-700) in Healthy Male Subjects: A Phase 1, Open-Label, Single-Dose Study.

Suri A, Pusalkar S, Li Y, Prakash S. Suri A, et al. Among authors: li y. Clin Pharmacol Drug Dev. 2016 May;5(3):180-7. doi: 10.1002/cpdd.234. Epub 2016 Jan 8. Clin Pharmacol Drug Dev. 2016. PMID: 27163496 Clinical Trial.

4

Preclinical absorption, distribution, metabolism, excretion and pharmacokinetics of a novel selective inhibitor of breast cancer resistance protein (BCRP).

Liao M, Chuang BC, Zhu Q, Li Y, Guan E, Yu S, Yang J, Prakash S, Xia CQ. Liao M, et al. Among authors: li y. Xenobiotica. 2018 May;48(5):467-477. doi: 10.1080/00498254.2017.1328147. Epub 2017 May 31. Xenobiotica. 2018. PMID: 28485193

5

Mass balance, routes of excretion, and pharmacokinetics of investigational oral [¹⁴C]-alisertib (MLN8237), an Aurora A kinase inhibitor in patients with advanced solid tumors.

Zhou X, Pusalkar S, Chowdhury SK, Searle S, Li Y, Ullmann CD, Venkatakrishnan K. Zhou X, et al. Among authors: li y. Invest New Drugs. 2019 Aug;37(4):666-673. doi: 10.1007/s10637-018-0693-7. Epub 2018 Nov 6. Invest New Drugs. 2019. PMID: 30397836 Clinical Trial.

6

Phase I study assessing the mass balance, pharmacokinetics, and excretion of [¹⁴C]-pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors.

Zhou X, Sedarati F, Faller DV, Zhao D, Faessel HM, Chowdhury S, Bolleddula J, Li Y, Venkatakrishnan K, Papai Z. Zhou X, et al. Among authors: li y. Invest New Drugs. 2021 Apr;39(2):488-498. doi: 10.1007/s10637-020-01017-x. Epub 2020 Oct 22. Invest New Drugs. 2021. PMID: 33089874 Free PMC article. Clinical Trial.

7

Clinical and Nonclinical Disposition and In Vitro Drug-Drug Interaction Potential of Felcisetrag, a Highly Selective and Potent 5-HT₄ Receptor Agonist.

Pusalkar S, Chowdhury SK, Czerniak R, Zhu X, Li Y, Balani SK, Ramsden D. Pusalkar S, et al. Among authors: li y. Eur J Drug Metab Pharmacokinet. 2022 May;47(3):371-386. doi: 10.1007/s13318-021-00751-8. Epub 2022 Feb 14. Eur J Drug Metab Pharmacokinet. 2022. PMID: 35157234 Free PMC article.

8

Investigation of the absolute bioavailability, mass balance, metabolism, and excretion of the cholesterol 24-hydroxylase inhibitor soticlestat in healthy volunteers.

Yin W, Ballard TE, Zhu SX, Hsiao S, Chen H, Li Y, Chowdhury SK, Stevenson A, Hui T, Hunt A, Asgharnejad M, Han S. Yin W, et al. Among authors: li y. Br J Clin Pharmacol. 2024 Feb;90(2):516-527. doi: 10.1111/bcp.15917. Epub 2023 Nov 12. Br J Clin Pharmacol. 2024. PMID: 37771051 Clinical Trial.

9

Metabolism and Excretion of [¹⁴C]Mobocertinib, a Selective Covalent Inhibitor of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations, in Healthy Male Subjects.

Chen H, Shah A, Kato S, Griffin R, Zhang S, Pusalkar S, Cohen L, Li Y, Chowdhury SK, Zhu SX. Chen H, et al. Among authors: li y. Drug Metab Dispos. 2024 Sep 16;52(10):1115-1123. doi: 10.1124/dmd.124.001841. Drug Metab Dispos. 2024. PMID: 39038951

10

Syntheses of C-13 and C-14-labeled versions of the investigational proteasome inhibitor MLN9708.

Plesescu M, Elliott EL, Li Y, Prakash SR. Plesescu M, et al. Among authors: li y. J Labelled Comp Radiopharm. 2013 Jul-Aug;56(9-10):464-70. doi: 10.1002/jlcr.3079. Epub 2013 Jul 9. J Labelled Comp Radiopharm. 2013. PMID: 24285522

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

238,349 results

Search Page

Filters